Credit Suisse’s Heron Therapeutics HRTX Stock Holding History

Credit Suisse’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-134,234	Closed	-$203K	–	3212
2023 Q1	$203K	Buy	134,234 +14,031	+12%	+$35.1K	﹤0.01%	3111
2022 Q4	$301K	Sell	120,203 -18,014	-13%	-$58K	﹤0.01%	3040
2022 Q3	$583K	Buy	138,217 +20,331	+17%	+$79.6K	﹤0.01%	2699
2022 Q2	$328K	Sell	117,886 -17,947	-13%	-$72.1K	﹤0.01%	3116
2022 Q1	$776K	Sell	135,833 -7,429	-5%	-$54.4K	﹤0.01%	2706
2021 Q4	$1.31M	Buy	143,262 +34,846	+32%	+$356K	﹤0.01%	3103
2021 Q3	$1.16M	Buy	108,416 +25,829	+31%	+$314K	﹤0.01%	3225
2021 Q2	$1.28M	Buy	82,587 +17,316	+27%	+$275K	﹤0.01%	3192
2021 Q1	$1.06M	Sell	65,271 -79,098	-55%	-$1.41M	﹤0.01%	3281
2020 Q4	$3.06M	Sell	144,369 -16,194	-10%	-$281K	﹤0.01%	2503
2020 Q3	$2.38M	Buy	160,563 +1,628	+1%	+$25.4K	﹤0.01%	2293
2020 Q2	$2.34M	Buy	158,935 +40,440	+34%	+$664K	﹤0.01%	2258
2020 Q1	$1.39M	Sell	118,495 -67,181	-36%	-$1.26M	﹤0.01%	2392
2019 Q4	$4.36M	Buy	185,676 +112,634	+154%	+$2.49M	﹤0.01%	1979
2019 Q3	$1.35M	Buy	73,042 +25,433	+53%	+$468K	﹤0.01%	2783
2019 Q2	$885K	Sell	47,609 -7,626	-14%	-$152K	﹤0.01%	3021
2019 Q1	$1.35M	Sell	55,235 -38,470	-41%	-$1.01M	﹤0.01%	2669
2018 Q4	$2.43M	Buy	93,705 +36,802	+65%	+$1.01M	﹤0.01%	2089
2018 Q3	$1.8M	Buy	56,903 +1,121	+2%	+$41.8K	﹤0.01%	2425
2018 Q2	$2.17M	Sell	55,782 -5,811	-9%	-$185K	﹤0.01%	2380
2018 Q1	$1.7M	Buy	61,593 +12,869	+26%	+$292K	﹤0.01%	2554
2017 Q4	$881K	Sell	48,724 -12,699	-21%	-$207K	﹤0.01%	3086
2017 Q3	$992K	Sell	61,423 -38,321	-38%	-$601K	﹤0.01%	3104
2017 Q2	$1.38M	Sell	99,744 -44,317	-31%	-$642K	﹤0.01%	2477
2017 Q1	$2.16M	Buy	144,061 +110,539	+330%	+$1.53M	﹤0.01%	2288
2016 Q4	$439K	Sell	33,522 -13,518	-29%	-$212K	﹤0.01%	3510
2016 Q3	$810K	Sell	47,040 -8,962	-16%	-$166K	﹤0.01%	3124
2016 Q2	$1.01M	Buy	56,002 +982	+2%	+$19.2K	﹤0.01%	2915
2016 Q1	$1.04M	Buy	55,020 +29,151	+113%	+$575K	﹤0.01%	2692
2015 Q4	$691K	Buy	25,869 +15,035	+139%	+$402K	﹤0.01%	3124
2015 Q3	$264K	Sell	10,834 -15,351	-59%	-$512K	﹤0.01%	3785
2015 Q2	$815K	Buy	+26,185	New	+$493K	﹤0.01%	3361
2014 Q2	–	Sell	-16,600	Closed	-$231K	–	4710
2014 Q1	$231K	Buy	+16,600	New	+$222K	﹤0.01%	4275

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Credit Suisse's HRTX Position: Q2 2023 in Review

Credit Suisse sold out of Heron Therapeutics (HRTX) in Q2 2023, closing a stake of 134,234 shares — an estimated $203K sold.

Credit Suisse first reported a position in HRTX in Q1 2014 and held it in 33 quarters. The position peaked at $4.36M in Q4 2019. 149 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

Credit Suisse reported no remaining Heron Therapeutics position as of Q2 2023 after selling out during the quarter.
Credit Suisse sold 134,234 Heron Therapeutics shares in Q2 2023, an estimated $203K.
Credit Suisse first reported a position in Heron Therapeutics in Q1 2014 and held it in 33 quarters.
Credit Suisse's Heron Therapeutics position peaked at $4.36M in Q4 2019.
149 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.